Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07758868 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Residual Neuromuscular Blockade and PACU Admission

StatusCompleted
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Notable Primary endpoint(s) modified Show 8 more changesShow less
    • Completed without a posted recruiting period
    • Final enrollment: 179 participants (planned 160)
    • Study completion date changed from estimate of Oct 1, 2026 to Sep 28, 2026
    • Secondary endpoints: 1 to 3
    • Study description revised
    • Site contact updated
    • Publications: details revised at 3 of 3 entries
    • Eligibility criteria shortened, about 4 words
  2. Minor Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Residual neuromuscular blockade (RNMB) remains an underrecognized postoperative safety concern associated with pulmonary complications, prolonged post-anesthesia care unit stay, and reduced patient satisfaction. Because conventional clinical tests are insufficiently sensitive and specific, current guidelines recommend quantitative neuromuscular monitoring to confirm adequate recovery, defined as a train-of-four ratio of ≥0.9. This prospective observational study included adult patients aged 18-90 years with ASA physical status I-IV who underwent elective surgery under general anesthesia with neuromuscular blocking agents. Demographic, clinical, anesthetic, surgical, and reversal-related variables were recorded. Postoperative neuromuscular recovery was quantitatively assessed at the adductor pollicis muscle using TOFscan® acceleromyography at the 10th postoperative minute. Patients were subsequently followed in either the PACU or surgical ward according to clinical indications, and postoperative adverse events were documented. The study aimed to evaluate the incidence and potential determinants of RNMB in accordance with contemporary neuromuscular monitoring guidelines.
Trial Details
NCT Number NCT07758868
Lead Sponsor Ankara Etlik City Hospital
Conditions
(from sponsor)
TOF
Enrollment 179 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov